Literature DB >> 31862541

Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition.

Megan Beckman1, Kevin Knox1, Zachery Koneval1, Carole Smith2, Suman Jayadev2, Melissa Barker-Haliski3.   

Abstract

Patients with Alzheimer's disease (AD) experience seizures at higher rates than the general population of that age, suggesting an underexplored role of hyperexcitability in AD. Genetic variants in presenilin (PSEN) 1 and 2 genes lead to autosomal dominant early-onset AD (ADAD); patients with PSEN gene variants also report seizures. Pharmacological control of seizures in AD may be disease-modifying. Preclinical efficacy of FDA-approved antiseizure drugs (ASDs) is well defined in young adult rodents; however, the efficacy of ASDs in aged rodents with chronic seizures is less clear. The mechanism by which ADAD genes lead to AD remains unclear, and even less studied is the pathogenesis of epilepsy in AD. PSEN variants generally all result in a biochemical loss of function (De Strooper, 2007). We herein determined whether well-established models of acute and chronic seizure could be used to explore the relationship between AD genes and seizures through investigating whether loss of normal PSEN2 function age-dependently influenced susceptibility to seizures and/or corneal kindling acquisition. PSEN2 knockout (KO) and age-matched wild-type (WT) mice were screened from 2- to 10-months-old to establish age-dependent focal seizure threshold. Additionally, PSEN2 KO and WT mice aged 2- and 8-months-old underwent corneal kindling such that mice were aged 3- and 9-months old at the beginning of ASD efficacy testing. We then defined the dose-dependent efficacy of mechanistically distinct ASDs on kindled seizures of young versus aged mice to better understand the applicability of corneal kindling to real-world use for geriatric patients. PSEN2 KO mice demonstrated early-life reductions in seizure threshold. However, kindling acquisition was delayed in 2-month-old PSEN2 KO versus WT mice. Young male WT mice took 24.3 ± 1.3 (S.E.M.) stimulations to achieve kindling criterion, whereas age-matched PSEN2 KO male mice took 41.2 ± 1.1 stimulations (p < .0001). The rate of kindling acquisition of 8-month-old mice was no longer different from WT. This study demonstrates that loss of normal PSEN2 function is associated with age-dependent changes in the in vivo susceptibility to acute seizures and kindling. Loss of normal PSEN2 function may be an underexplored molecular contributor to seizures. The use of validated models of chronic seizures in aged rodents may uncover age-related changes in susceptibility to epileptogenesis and/or ASD efficacy in mice with AD-associated genotypes, which may benefit the management of seizures in AD.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Aging; Alzheimer's; Carbamazepine; Corneal kindling; Diazepam; Epilepsy; Lamotrigine; Levetiracetam; Presenilin; Seizures; Valproic acid

Year:  2019        PMID: 31862541      PMCID: PMC7462087          DOI: 10.1016/j.nbd.2019.104719

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  76 in total

1.  Presenilins regulate the cellular activity of ryanodine receptors differentially through isotype-specific N-terminal cysteines.

Authors:  Andrew J Payne; Bryan C Gerdes; Yuliya Naumchuk; Audrey E McCalley; Simon Kaja; Peter Koulen
Journal:  Exp Neurol       Date:  2013-09-09       Impact factor: 5.330

2.  Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression.

Authors:  Diede W M Broekaart; Jasper J Anink; Johannes C Baayen; Sander Idema; Helga E de Vries; Eleonora Aronica; Jan A Gorter; Erwin A van Vliet
Journal:  Epilepsia       Date:  2018-09-08       Impact factor: 5.864

3.  Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels.

Authors:  Meir Bialer; Roy E Twyman; H Steve White
Journal:  Epilepsy Behav       Date:  2004-12       Impact factor: 2.937

4.  Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models.

Authors:  Nicole M Rowley; H Steve White
Journal:  Epilepsy Res       Date:  2010-10-14       Impact factor: 3.045

5.  Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.

Authors:  Melissa L Barker-Haliski; Fabiola Vanegas; Matthew J Mau; Tristan K Underwood; H Steve White
Journal:  Epilepsia       Date:  2016-07-28       Impact factor: 5.864

6.  Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice.

Authors:  Vassilios Beglopoulos; Xiaoyan Sun; Carlos A Saura; Cynthia A Lemere; Richard D Kim; Jie Shen
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

7.  Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.

Authors:  A Matagne; H Klitgaard
Journal:  Epilepsy Res       Date:  1998-06       Impact factor: 3.045

Review 8.  Epilepsy and cognitive impairments in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Arch Neurol       Date:  2009-02-09

9.  Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease.

Authors:  Alice D Lam; Gina Deck; Alica Goldman; Emad N Eskandar; Jeffrey Noebels; Andrew J Cole
Journal:  Nat Med       Date:  2017-05-01       Impact factor: 53.440

10.  A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task Force.

Authors:  Melissa Barker-Haliski; Lauren C Harte-Hargrove; Teresa Ravizza; Ilse Smolders; Bo Xiao; Claudia Brandt; Wolfgang Löscher
Journal:  Epilepsia Open       Date:  2018-09-15
View more
  5 in total

Review 1.  Can Old Animals Reveal New Targets? The Aging and Degenerating Brain as a New Precision Medicine Opportunity for Epilepsy.

Authors:  Aaron Del Pozo; Leanne Lehmann; Kevin M Knox; Melissa Barker-Haliski
Journal:  Front Neurol       Date:  2022-04-28       Impact factor: 4.086

2.  Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.

Authors:  Zachery Koneval; Kevin M Knox; Ali Memon; Dannielle K Zierath; H Steve White; Melissa Barker-Haliski
Journal:  Epilepsia       Date:  2020-08-05       Impact factor: 5.864

3.  Early changes in synaptic and intrinsic properties of dentate gyrus granule cells in a mouse model of Alzheimer's disease neuropathology and atypical effects of the cholinergic antagonist atropine.

Authors:  David Alcantara-Gonzalez; Elissavet Chartampila; Chiara Criscuolo; Helen E Scharfman
Journal:  Neurobiol Dis       Date:  2021-01-20       Impact factor: 5.996

Review 4.  Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation.

Authors:  Leanne Lehmann; Alexandria Lo; Kevin M Knox; Melissa Barker-Haliski
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

Review 5.  The clinical correlation between Alzheimer's disease and epilepsy.

Authors:  Dandan Zhang; Siyuan Chen; Shoucheng Xu; Jing Wu; Yuansu Zhuang; Wei Cao; Xiaopeng Chen; Xuezhong Li
Journal:  Front Neurol       Date:  2022-07-22       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.